Abstract
Stability-indicating reversed-phase high-performance liquid chromatography (RP-HPLC) and normal-phase high-performance thin-layer chromatography (NP-HPTLC) methods have been developed for the determination of palonosetron which is a potent antiemetic drug used with chemotherapy. Forced degradation studies were performed on palonosetron to study its stability behavior. The drug was subjected to acid, base, neutral hydrolysis, oxidation, thermal and photolytic conditions. Mass analysis has been performed to elucidate the oxidative degradants by Advion compact mass spectrometer. HPLC separation was achieved on PerfectChrom 100 C4 (250 × 4.6 mm, 5 μm particle size) column using buffer (20 mM dipotassium hydrogen orthophosphate, adjusted with phosphoric acid to pH 2.5):acetonitrile:methanol (60:30:10, v/v) as the mobile phase with isocratic mode at a flow rate of 1 mL/min using photodiode array detector (PAD) at 210 nm. The method showed adequate sensitivity concerning linearity, accuracy and precision over the range of 0.1–10 μg/mL. Limit of detection (LOD) and limit of quantification (LOQ) were determined to be 0.03 μg/mL and 0.09 μg/mL, respectively. HPTLC separation was carried out on aluminum plates pre-coated with silica gel 60 F254 using methanol:ammonia (10:0.5, v/v) as the mobile phase. CAMAG scanner was operated at 254 nm for the densitometric measurement in the absorbance mode. A polynomial relationship was constructed in concentration range of 0.1–2 μg/band, with LOD and LOQ 0.02 μg/band and 0.06 μg/band, respectively. The cited chromatographic methods were successfully applied to the determination of palonosetron in the presence of its degradation products and additives in the commercially available vials. Method validation was performed as per the ICH guidelines confirming methods robustness to be used in quality control laboratories. Statistical comparisons have been performed between the results of the cited chromatographic methods and those of the official one using Student’s t test and F test values at 95% confidence interval level, revealing good accuracy and precision.
Similar content being viewed by others
References
Klick S, Muijselaar PG, Waterval J, Eichinger T, Korn C, Gerding TK, Debets AJ, van de Griend CS, van den Beld C, Somsen GW, Jong GJD (2005) Pharm. Technol 29:48–66
FDA Guidance for Industry: Impurities in Drug Substances, Food and Drug Administration, Rockville, MD, 2005
Patel BMRD, Prajapati PN, Agrawal YK (2014) J. Pharm. Anal 4:159–165
Kumar V, Bharadwaj R, Gupta G, Kumar S (2015) Pharm Chem J 2:30–40
Kastner M (2000) Protein liquid chromatography, vol 61. Elsevier Science, Amsterdam
M. C. García-Alvarez-Coque, J. J. Baeza-Baeza, G. Ramis-Ramos, Reversed phase liquid chromatography Analytical Separation Science: Wiley-VCH 2015. 159–198
A. De Leon, Proc (Bayl Univ Med Cent) 19 (2006) 413–416
Brayfield A (2018) Martindale: the complete drug reference, 39th edn. Pharmaceutical Press, London
United States Pharmacopeia, USP 41, NF 36, Rockville, MD, 2018
Murthy MV, Srinivas K, Kumar R, Mukkanti K (2011) J Pharm Biomed Anal 56:429–435
Parekh D, Patel CJ, Patel MM (2018) World J Pharm Res 7:723–736
Damle MC, Agrawal AA (2015) Am J PharmTech Res 5:275–286
Jain PS, Chavan RS, Bari PR, Patil SS, Surana SJ, Adv J (2015) Drug Deliv 2
Pathi PJ, Raju NA (2012) Asian J Pharm Technol 2:77–79
Inturi S, Inturi R, Venkatesh G (2011) Pharm Sin 2:223–234
Li P, Ma P, Wang Y, Tong W, Wang J, Wu C, Liu L (2012) J Chromatogr B 895-896:10–16
Wang Y, Wang Y, Zhang P, Lu Z, Gu Y, Ou N (2011) Determination of palonosetron in human urine by LC-MS/MS. Bioanalysis 3:1337–1342
Yang S, Qin F, Wang D, Li N, Li F, Xiong Z (2012) Determination of palonosetron in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. J Pharm Biomed Anal 57:13–18
Ding L, Chen Y, Yang L, Wen A (2007) Determination of palonosetron in human plasma by liquid chromatography-electrospray ionization-mass spectrometry. J Pharm Biomed Anal 44:575–580
Zhang W, Feng F, Le W, Wang H, Zhu L (2008) Chromatographia 68:193–199
Tian K, Chen H, Tang J, Chen X, Hu Z (2006) Enantioseparation of palonosetron hydrochloride by micellar electrokinetic chromatography with sodium cholate as chiral selector. J Chromatogr A 1132:333–336
Radhakrishnanand P, Subba Rao DV, Himabindu V (2008) Chromatographia 69:369–373
Xiao-rong Y, Min S, Tai-jun H (2008) Chin. J. New Drugs 10
Parambi DGT, Mathew SM, Ganesan V (2011) Int J Chem Sci 4:1619–1624
ICH, Stability testing of new drug substances and products, ICH Harmonised Tripartite Guideline Q1A (R2), Vol. 4, Geneva, 2003, 1–24
ICH. Q2 (R1): Validation of analytical procedures: text and methodology. in International Conference on Harmonization, Geneva, 2005
Moffat A, Osselton M, Widdop B (2011) Clarke’s analysis of drugs and poisons, 4th edn. Pharmaceutical Press, London
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tantawy, M.A., Alweshahy, S., Elshabasy, D.A. et al. Butyl-based reversed-phase high-performance liquid chromatography and silica normal-phase high-performance thin-layer chromatography methods for the determination of palonosetron in the presence of degradation products and dosage form additives. JPC-J Planar Chromat 33, 149–160 (2020). https://doi.org/10.1007/s00764-020-00014-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00764-020-00014-3